Aurora kinase inhibitors: Progress towards the clinic
Open Access
- 18 February 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 30 (6), 2411-2432
- https://doi.org/10.1007/s10637-012-9798-6
Abstract
Summary: The Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation in Drosophila melanogaster. They soon became the focus of much attention because of their importance in human biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered, and are currently under development. The binding modes of Aurora kinase inhibitors to Aurora kinases share specific hydrogen bonds between the inhibitor core and the back bone of the kinase hinge region, while others parts of the molecules may point to different parts of the active site via noncovalent interactions. Currently there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and status of Aurora kinase inhibitors in preclinical, Phase I, and Phase II clinical studies, with particular emphasis on the mechanisms of action and resistance to these promising anticancer agents. We also discuss the validity of Aurora kinases as oncology targets, on/off-target toxicities, and other important aspects of overall clinical performance and future of Aurora kinase inhibitors.Keywords
This publication has 96 references indexed in Scilit:
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaBlood, 2010
- Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)Pediatric Blood & Cancer, 2010
- In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465British Journal of Haematology, 2009
- A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- Modulation of kinase‐inhibitor interactions by auxiliary protein binding: Crystallography studies on Aurora A interactions with VX‐680 and with TPX2Protein Science, 2008
- Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cellsBritish Journal of Cancer, 2007
- A Microtubule-Independent Role for Centrosomes and Aurora A in Nuclear Envelope BreakdownDevelopmental Cell, 2007
- Aurora B expression correlates with aggressive behaviour in glioblastoma multiformeJournal of Clinical Pathology, 2006
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancersThe EMBO Journal, 1998